To contribute to the elimination of schistosomiasis by addressing the medical need of infected preschool-aged children, including infants and toddlers, a group currently devoid of a suitable treatment.
To develop and provide a suitable pediatric praziquantel formulation with acceptable palatability, proven efficacy and safety for treating schistosomiasis in preschool-aged children.
To make a meaningful contribution to tropical medicine and health innovation in endemic countries. We aim to provide scientific evidence and potentially trigger the creation of policies for prevention and treatment of schistosomiasis in children.
A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation consists of small, orodispersible tablets with an (improved) acceptable taste.